• Notifications
    This feature only available to registered users.
  • Alerts
    This feature only available to registered users
  • Welcome Guest!
  • Login Signup

Stock [ BUY ] / [ SELL ] Trading Strategies
. [ Show Details ]

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

INO [ Inovio Pharmaceuticals Inc ]
Last Trade 21.79 Date 8/6/2020
Change % 7.27 % Price Change 1.48
Open 20.24 52 Week High 33.79
High 22.13 52 Week Low 1.915
Low 19.82 Type stock
Volume 16514252 Average Volume 7075254
Prev Close 20.315 Stock Exchange NASDAQ
Bid 21.86 Ask 21.88
Bid Size 3 Ask Size 1
1st Yr Estimated EPS Growth -0.3504 2nd Yr Estimated EPS Growth -0.5132
2 Years Forward Earning Yield -0.0182 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 1.1659 Book Value Yield 0.0574
Buy Back Yield CAPE Ratio
Cash Return -0.0267 Cash Flow per Share -0.8611
Cash Flow Yield -0.0424 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.0576 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue 315.2319 EV / Pre Tax Income
EV / Revenue 1165.1611 EV / Total Asset 8.9704
Expected Dividend Growth Rate Free Cash Flow per Share -0.8656
Free Caash Flow Ratio Free Cash Flow Yield -0.0426
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.0374 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 17.424284 PB Ratio 10 Year Growth 0.230768
PB Ratio 3 Year Growth 26.903905 Cash Ratio 3 Year Average 513.5905
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average PE Ratio 10 Year Growth
PE Ratio 10 Year High PE Ratio 10 Year Low
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month 1.04501
Price to Cash Ratio 11.895384 Price / EBITDA
Price to Sales Ratio 821.383053 Price to Sales Ratio 10 Year Growth 0.51943
Price to Sales Ratio 3 Year Avg 87.855274 Price to Sales Ratio 5 Year Avg
Sale per Share 0.0247 Sales Yield 0.0012
Sustainable Growth Rate -0.9357 Tangible Book Value per Share 1.0769
Tangible Book Value per Share 3 year Avg 0.9004 Tangible Book Value per Share 5 year Avg 1.3823
Total Asset per Share 2.1438 Total Yield
Working Capital per Share 1.5386 Working Capital per Share 3 Year Avg 0.9328
Working Capital per Share 5 Year Avg 1.2858 Beta 1.102538
Company Profile

Inovio Pharmaceuticals, Inc. engages in the discovery, development, and delivery of DNA vaccines with a focus on cancers and infectious diseases. Its SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against evolving, unmatched strains of pathogens, such as influenza. The company?s proprietary electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company?s clinical programs include trials for human papillomavirus/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus, and human immunodeficiency virus vaccines. It also advances preclinical research for seasonal/pandemic influenza vaccine. Inovio Pharmaceuticals? partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. on May 14, 2010. Inovio Pharmaceuticals was founded in 1983 and is headquartered in Blue Bell, Pennsylvania.